In a bold move, the UK’s pharmaceutical giant, valued at a staggering $140 billion, has allegedly reached out to its American counterpart, boasting a market value of around $96 billion, to explore the possibility of a monumental merger. This informal approach is seen as a gauge of the US company’s interest in what could be the largest deal in the history of the pharmaceutical industry. Historically, the American firm has focused on acquiring smaller entities, shying away from massive mergers with Big Pharma companies. However, if successful, this union would create the world’s largest pharmaceutical company in terms of market value, surpassing previous records like the $87.6 billion deal between Bristol-Myers Squibb and Celgene Corporation in 2019.
The global disruption caused by the COVID-19 pandemic has brought the pharmaceutical industry to the forefront, with companies racing to develop treatments and vaccines. The American firm has emerged as a leader in providing COVID-19 therapies, with its antiviral treatment, Remdesivir, proven to reduce patient recovery time. With projected annual sales of over $7 billion by 2022, the drug’s success could be a game-changer. Meanwhile, the UK company is nearing the final stages of its own COVID-19 vaccine development. A merger would significantly strengthen both companies’ influence in the fight against coronaviruses.
The American firm has demonstrated impressive financial performance in recent years, boasting a net income of $5.4 billion in 2019. The success of Remdesivir is expected to further boost profits in 2020, with revenues growing 5% year-on-year in the first quarter. While large pharma deals often occur when one party is financially distressed, the current circumstances make an agreeable merger uncertain.
Leave a Reply